anti-inflammatory agent

Anti-inflammatory agent 49 is a potent inhibitor of Drp1-Fis1 interaction, inhibits GTPase, and can be used in the study of diseases caused by mitochondrial dysfunction.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Anti-inflammatory agent 52 (compound 7c) is an orally active, selective COX-2 inhibitor with demonstrated anti-HT29 metastatic activity, causing periodic arrest in the S phase and G2 M phase. This agent exhibits moderate anti-inflammatory efficacy alongside a notable safety profile. Additionally, it possesses the uncommon capability of inhibiting tumor development in a mouse model, indicative of anti-cancer properties [1].

Compound 2v (Anti-inflammatory agent 45) demonstrates anticancer properties with direct inhibitory impacts on the proliferation of various blood malignancies, such as leukemia, lymphoma, and myeloma cell lines. It induces apoptosis and suppresses nitric oxide production in HL60 leukemia cells (IC50 = 14.7 μM) [1].

Anti-inflammatory agent 8 (compound 13), designated as an anti-inflammatory agent 8, displays enhanced activity on the COX-2 enzyme compared to COX-1, with an IC50 value of 0.09 nM, and exhibits oral bioavailability [1].

Anti-inflammatory agent 22 (compound 14a) is a potent orally active compound with anti-inflammatory properties, effectively inhibiting LPS-induced TNF-α production with an IC50 of 14.6 μM. Additionally, Anti-inflammatory agent 22 prevents adipogenesis and effectively suppresses limb lymphedema volume in mice, holding promise for treating inflammation-related conditions, particularly lymphedematous tissue disorders [1].

Anti-inflammatory agent 62 mitigates acetaminophen-induced hepatotoxicity in HepG2 cells by modulating inflammatory and oxidative stress pathways [1].

Compound 13, also known as Anti-inflammatory agent 57 and classified as a pyranocoumarin, is a natural product extracted from the roots of Peucedanum praeruptorum. This compound possesses both multidrug-resistance (MDR) reversal properties and anti-inflammatory effects [1].

Compound 29 (Compound 7) is an anti-inflammatory agent that exhibits hepatoprotective activity [1].

Compound 5b (Anti-inflammatory agent 61) is a potent anti-inflammatory agent that diminishes TNF-α expression in LPS-induced inflammation within RAW 264.7 cells and mitigates APAP-induced inflammation in HepG2 cells [1].

Anti-inflammatory agent 56 (Compound 9), a selective COX-2 inhibitor with an IC50 of 0.54 μM, exhibits antioxidant and anti-inflammatory properties by inhibiting oxidative stress-induced cell death and neuroinflammation through the suppression of Keap1, COX-2, and iNOS. It demonstrates low acute toxicity in mice with an LD50 of 1000 mg kg [1].

Anti-inflammatory agent 23 is an anti-inflammatory agent that inhibits LPS-activated NO production (IC50: 0.449 μM). anti-inflammatory agent 23 exhibits good affinity for p65 protein.

Anti-inflammatory agent 38 (compound 23d) is a potent Nrf2/HO-1 pathway inhibitor, with an IC 50 value of 0.38 μM for NO . Nrf2/HO-1-IN-1 can significantly reduce the level of ROS in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory [1] .

Anti-inflammatory agent 65 (compound 29), a Hederagonic acid derivative, exhibits potent activity by inhibiting nitric oxide (NO) release, nuclear translocation of IRF3 and p65, and disrupting the STING IRF3 NF-κB signaling pathway, thus attenuating the inflammatory response [1].

Anti-inflammatory agent 58 exhibits IL-1β inhibition with an IC50 value of 1.08 μM and suppresses pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation [1].

Compound 43, also known as compound 3, is a 6-methoxyflavonol glycoside exhibiting anti-inflammatory activity. This agent, along with compound 44, is extractable from the aerial parts of Tetragonia tetragonoides [1].

Anti-inflammatory agent 6 exhibits anti-inflammatory potential by blocking the phosphorylation of Iκb kinase α/β (IKKα/β), IκBα and nuclear factor kB p65 (NF-κb p65), which are key controllers of inflammation.

Anti-inflammatory agent 50 (compound a1), a derivative of Fusidic acid, exerts its effects through inhibition of inflammatory mediators including NO, IL-6, and TNF-α. It mitigates acute lung injury by modulating these mediators and suppressing the MAPK, NF-κB, and NLRP3 inflammasome signaling pathways [1].

Anti-inflammatory agent 52 (compound 7j) is an orally active, selective COX-2 inhibitor that induces G2 M phase arrest and exhibits anti-HT29 transfer activity. It demonstrates moderate anti-inflammatory efficacy and a notable safety profile, and uniquely inhibits tumor growth in mouse models, indicative of its anticancer properties [1].

Anti-inflammatory agent 48 functions by inhibiting the NF-κB signaling pathway and activating HO-1 expression, characterizing its role as an anti-inflammatory agent [1].

Anti-inflammatory agent 54 (compound 9c), a Coixol derivative, exhibits anti-inflammatory properties by inhibiting the NF-κB pathway and reducing the expression of pro-inflammatory cytokines such as iNOS, TNF-α, IL-6, and IL-1β. It effectively suppresses LPS-induced nitric oxide (NO) production in RAW264.7 macrophages with an IC50 of 2.4 μM and demonstrates in vivo efficacy in a mouse auricular edema model [1].

Compound 9j (anti-inflammatory agent 55), a Coixol derivative, exhibits anti-inflammatory properties by inhibiting the NF-κB pathway and reducing the expression of iNOS, TNF-α, IL-6, and IL-1β. It notably suppresses LPS-induced nitric oxide (NO) production in RAW264.7 macrophages with an IC50 of 0.8 μM and demonstrates anti-inflammatory effects in vivo using a mouse auricular edema model [1].

Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial agent used in tuberculosis (TB) research. It inhibits the growth of Mtb H37Rv and M299 with MIC 50 values of 1.3 and 6.9 μM, respectively. Additionally, it reduces inflammation by suppressing iNOS expression and inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 16 (compound 14) is a potent peptidomimetic that significantly reduces the expression levels of TNFα, NO, CD40, and CD86 [1].

Anti-inflammatory agent 33, a potent p38α inhibitor, effectively reduces NO production and suppresses LPS-induced expression of iNOS, COX-2, p-p38α, and p-MK2 proteins, thereby demonstrating anti-inflammatory activity.

Anti-inflammatory Agent 7 suppresses proinflammatory cytokines by hindering the NF-κB/MAPK signaling pathway in both LPS-treated RAW 264.7 cells and mice.

Anti-inflammatory agent 35 is a potent anti-inflammatory agent.

Anti-inflammatory agent 64 (compound 4b) demonstrates antioxidant and anti-inflammatory properties, effectively inhibiting IL-6 and TNF-α secretion and reducing paw edema [1] in both in vitro and in vivo studies.

Anti-inflammatory agent 60 (compound 21) inhibits nitric oxide production, presenting an IC50 of 12.95 μM, and reduces iNOS, phosphorylated p65, and β-catenin expression in a concentration-dependent manner [1].

Flo8, an anti-inflammatory and antioxidant agent, effectively suppresses the release of reactive oxygen species (ROS) and nitric oxide (NO) while inhibiting neuronal apoptosis by modulating inflammatory and apoptotic signaling pathways, showcasing potential utility in Parkinson's Disease (PD) research [1].

Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].

Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial agent used in tuberculosis (TB) research, inhibiting the growth of Mtb H37Rv and M299 with MIC50 values of 2.3 and 7.8 μM, respectively. This compound also suppresses the expression of iNOS, thereby inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 1 is a chemical compound designated for reducing inflammation, structurally characterized by a [carboxyl acid], [oxygen], and [hydrocarbon] ring, with notable efficacy in mitigating inflammatory responses.

Anti-inflammatory agent 51 is an amide sulfonamide derivative with anti-inflammatory and potentially anti-tumor activity and inhibition of NF-κB activation, which can be used to study acute lung injury and ulcerative colitis.

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 9 (compound 28) is a benzimidazothiazole derivative derived from tilomisole, exhibiting higher COX-2 enzyme affinity than COX-1, thereby demonstrating promising anti-inflammatory properties and oral bioavailability [1].

Anti-inflammatory agent 63 exhibits potent inhibitory activity (EC50 = 5.33±0.57 μM) against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW264.7 cells [1].

Anti-inflammatory agent 5 effectively inhibits nitric oxide (NO) production in lipopolysaccharide-induced BV-2 microglial cells.

Compound 28 (Compound 9) is an anti-inflammatory agent with hepatoprotective activity [1].

Anti-inflammatory agent 36 is an anti-inflammatory agent that exhibited dose-dependent inhibition of LPS-induced release of TNF-a and IL-6 in active RAW 264.7 mouse macrophages (IC50 = 3.69 μM and 3.68 μM, respectively).

Anti-inflammatory agent 19 inhibits NO (IC50: 36.00 μM). anti-inflammatory agent 19 exhibits an inhibitory effect on HMGB1-induced late inflammatory responses. anti-inflammatory agent 19 can be used to study late inflammatory diseases such as Coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 40 is a promising, orally-active compound with anti-malarial and anti-inflammatory properties that effectively inhibits carrageenan-induced paw swelling in vivo.

Compound 7h (Anti-inflammatory agent 46), exhibiting nitric oxide (NO) inhibitory properties, demonstrates high affinity for iNOS through low binding energies and effectively reduces swelling in mouse models at a dose of 10 mg kg [1].

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Anti-inflammatory agent 10 is a tilomisole-based benzimidazole-thiazole derivative that is orally active. anti-inflammatory agent 10 is more active against COX-2 enzymes than COX-1.

Anti-inflammatory agent 31 (enone 17), an andrographolide derivative, inhibits NF-κB activation by blocking the PI3K Akt and ERK1 2 MAPK pathways. It effectively restores intracellular GSH levels and exhibits protective effects on the liver [1].

Anti-inflammatory agent 12 is a pentacyclic triterpene compound that showed a significant bias in LPS-induced inflammatory responses (IC50: 2.22 μM). anti-inflammatory agent 12 has potential for use in inflammatory disease research.

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Anti-inflammatory agent 58 is characterized by its ability to inhibit IL-1β with an IC50 value of 2.28 μM. Furthermore, it reduces pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation [1].

Compound 1 (Anti-inflammatory agent 44) is a 6-methoxyflavonol glycoside exhibiting anti-inflammatory properties, and it can be extracted from the aerial parts of Tetragonia tetragonoides [1].